

Sona Balogov

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4808994/sona-balogova-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

1,262
citations

17
h-index

35
g-index

63
ext. papers

1,538
ext. citations

2.5
avg, IF

3.82
L-index

#	Paper	IF	Citations
51	Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-DOTA-conjugated somatostatin receptor targeting peptides and F-DOPA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1588-1601	8.8	179
50	Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1699-706	8.9	153
49	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137	8.8	113
48	A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies. <i>Journal of Clinical Endocrinology and Metabolism (United States)</i> , 2015, 94, e1701	1.8	113
47	Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4531-6	5.6	101
46	18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 943-66	8.8	89
45	Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 448-57	1.4	71
44	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1995-2004	8.8	50
43	Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. <i>Nuclear Medicine Communications</i> , 2010, 31, 389-97	1.6	41
42	Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. <i>Radiology and Oncology</i> , 2014, 48, 228-34	3.8	38
41	Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1266-9	8.8	34
40	Diagnosis of bone metastasis: recent comparative studies of imaging modalities. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 55, 374-410	1.4	33
39	Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. <i>Molecular Imaging and Biology</i> , 2008, 10, 364-73	3.8	30
38	Impact of FDG-PET to detect recurrence of head and neck squamous cell carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2007, 137, 647-53	5.5	25
37	What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?. <i>Current Radiopharmaceuticals</i> , 2013, 6, 96-105	1.8	23
36	Can we achieve a radionuclide radiation dose equal to or less than that of 99mTc-hydroxymethane diphosphonate bone scintigraphy with a low-dose 18F-sodium fluoride time-of-flight PET of diagnostic quality?. <i>Nuclear Medicine Communications</i> , 2013, 34, 417-25	1.6	20
35	A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. <i>Nuclear Medicine Communications</i> , 2012, 33, 757-65	1.6	20

34	18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study. <i>PLoS ONE</i> , 2018, 13, e0191487	3.7	14
33	Use of choline PET for studying hepatocellular carcinoma. <i>Clinical and Translational Imaging</i> , 2014, 2, 103-113	2	12
32	Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake. <i>Clinical Nuclear Medicine</i> , 2013, 38, 200-2	1.7	10
31	Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study. <i>Clinical Nuclear Medicine</i> , 2014, 39, 951-9	1.7	8
30	Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. <i>Radiology and Oncology</i> , 2014, 48, 20-8	3.8	7
29	Prognostic value of functional tumor burden on 68Ga-DOTATOC PET/CT in patients with pancreatic neuro-endocrine tumors. <i>Neoplasma</i> , 2019, 66, 140-148	3.3	6
28	Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1220-30	8.8	5
27	La fluorocholine(18F) a une utilité clinique dans le cancer de la prostate et le carcinome hépatocellulaire parfois chez le même malade. <i>Medecine Nucleaire</i> , 2010, 34, 378-382	0.1	5
26	Comparison of F-sodium fluoride PET/CT, F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. <i>BMC Medical Imaging</i> , 2020, 20, 25	2.9	3
25	Tomographie par émission de positons et cancer de la prostate. <i>Medecine Nucleaire</i> , 2008, 32, 409-417	0.1	3
24	Radiosynoviorthesis of acromioclavicular joint using 169Er-citrate: prospective evaluation of efficacy. <i>Nuclear Medicine Review</i> , 2018, 21, 26-31	0.3	3
23	Effet du traitement par pegfilgrastim sur la fixation de la fluorocholine (18F) par la moelle osseuse. <i>Medecine Nucleaire</i> , 2012, 36, 413-418	0.1	2
22	Récidive biologique de cancer de la prostate : intérêt de la TEP/TDM à la fluorocholine (18F) du corps entier. <i>Medecine Nucleaire</i> , 2010, 34, 540-545	0.1	2
21	TEP/TDM au fluorure (18F) de sodium pour la détection des métastases osseuses du cancer de la prostate. Description de l'étude Fluprostic de comparaison de la TEP/TDM au fluorure (18F) de sodium à l'IRM corps entier dans cette indication. <i>Medecine Nucleaire</i> , 2009, 33, 388-397	0.1	2
20	Controversies in the management of clinical stage I testicular seminoma. <i>Central European Journal of Urology</i> , 2016, 69, 35-9	0.9	2
19	Imagerie du cancer de la prostate oligométastatique, le point de vue du médecin nucléaire. <i>Medecine Nucleaire</i> , 2019, 43, 227-235	0.1	1
18	Strengths and limitations of using fluorine-fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 477-485	4.1	1
17	TEP/TDM au 68 Ga-PSMA-11 quand la 18 F-fluorocholine ne localise pas la récidive biologique du cancer de la prostate : propos d'un cas et revue de la littérature. <i>Medecine Nucleaire</i> , 2017, 41, 453-457	0.1	1

16	Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l'enregistrement de la fluorocholine (18F) : analyse sur deux ans à l'Hôpital Tenon. <i>Medecine Nucleaire</i> , 2012, 36, 363-370	0.1	1
15	Metabolic syndrome and its effect on aortic stiffness in premenopausal women. <i>Bratislava Medical Journal</i> , 2013, 114, 279-82	1.7	1
14	TEP/TDM à la fluorométhylcholine-(18F) dans l'imagerie de la récidive du cancer de la prostate : jalons pour un PHRC national. <i>Medecine Nucleaire</i> , 2007, 31, 338-344	0.1	1
13	Interference of Known or Suspected Endometriosis in Reporting FDG PET/CT Performed in Another Indication.. <i>Clinical Nuclear Medicine</i> , 2022, 47,	1.7	1
12	Tomographie d'émission de positons et radiopharmaceutiques spécifiques en oncologie : exemples d'application. <i>Medecine Nucleaire</i> , 2009, 33, 152-160	0.1	0
11	Stage I testicular seminoma risk-adapted therapeutic management. <i>Neoplasma</i> , 2021, 68, 613-620	3.3	0
10	Signification d'une hyperfixation prostatique du fluorodésoxyglucose (18F) chez un patient sans antécédent de cancer de la prostate. Cas cliniques, revue et méta-analyse de la littérature. <i>Medecine Nucleaire</i> , 2014, 38, 266-274	0.1	
9	La TEP des tumeurs neuroendocrines de l'intestin grêle. <i>Medecine Nucleaire</i> , 2014, 38, 235-239	0.1	
8	Reply. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 172	8.8	
7	Étude rétrospective des conséquences de l'administration d'une préparation de FDG contenant de 5 % à 10 % de fluorure (18F) libre sur l'imagerie TEP/TDM de l'os sain et des foyers osseux pathologiques. Comparaison avec un groupe apparié de patients ayant reçu une préparation de FDG contenant moins de 5 % de fluorure (18F) libre. <i>Medecine Nucleaire</i> , 2012, 36, 371-377	0.1	
6	TEP/TDM au FDG et hibernome : à propos d'un cas. <i>Medecine Nucleaire</i> , 2012, 36, 408-412	0.1	
5	La concentration plasmatique de PTH permet-elle de sélectionner les patients atteints d'hyperparathyroïdie secondaire pour bénéficier de la scintigraphie double isotope MIBI (99mTc)/123I préopératoire ?. <i>Medecine Nucleaire</i> , 2010, 34, 388-392	0.1	
4	Registered and potential indications of FDG PET/CT in breast carcinoma. <i>Archive of Oncology</i> , 2012, 20, 152-157	0.2	
3	FDG and FCH PET/CT of Multiple Myeloma at Various Clinical Situations: Lesion Detection, Proposal for a Patient-Based "Summ" Score and Reproducibility of Scoring. <i>Blood</i> , 2018, 132, 4487-4487	2.2	
2	Hepatic Cavernous Hemangioma Mimicking Metastasis of Midgut Neuroendocrine Neoplasia on 18F-Fluorodihydroxyphenylalanine PET/CT. <i>Clinical Nuclear Medicine</i> , 2022, 47, 76-78	1.7	
1	32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016. <i>EJNMMI Research</i> , 2016, 6, 32	3.6	